Pre-treatment characteristics and long-term outcomes of recurrent-metastatic head and neck cancer patients treated with immune checkpoint inhibitors

被引：1
|
作者：
Issa, M. [1 ]
Schultz, T. [1 ]
Xu, M. [1 ]
Bhateja, P. [1 ]
Karivedu, V. [1 ]
Dibs, K. [2 ]
Old, M. [3 ]
Kang, S. [3 ]
Gamez, M. [2 ]
Grecula, J. [2 ]
Jhawar, S. [2 ]
Mitchell, D. [2 ]
Seim, N. [3 ]
Agrawal, A. [3 ]
Ozer, E. [3 ]
Baliga, S. S. B. E. [2 ]
Carrau, R. [3 ]
Rocco, J. [3 ]
Blakaj, D. [2 ]
Bonomi, M. [1 ]
机构：
[1] Ohio State Univ, Comprehens Canc Ctr James, Med Oncol, Columbus, OH 43210 USA
[2] Ohio State Univ, Comprehens Canc Ctr James, OSUCCC, Radiat Oncol Dept, Columbus, OH 43210 USA
[3] Ohio State Univ, James Canc Hosp, Otolaryngol, Columbus, OH 43210 USA
来源：
ANNALS OF ONCOLOGY | 2020年 / 31卷
关键词：
D O I：
10.1016/j.annonc.2020.08.1063
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
948P
引用
收藏
页码：S674 / S675
页数：2
相关论文
共 50 条
  • [41] Thromboembolism in Patients with Metastatic Urothelial Cancer Treated with Immune Checkpoint Inhibitors
    Iris Y. Sheng
    Shilpa Gupta
    Chandana A. Reddy
    Dana Angelini
    Pauline Funchain
    Tamara A. Sussman
    Joseph Sleiman
    Moshe C. Ornstein
    Keith McCrae
    Alok A. Khorana
    Targeted Oncology, 2022, 17 : 563 - 569
  • [42] Thromboembolism in Patients with Metastatic Urothelial Cancer Treated with Immune Checkpoint Inhibitors
    Sheng, Iris Y.
    Gupta, Shilpa
    Reddy, Chandana A.
    Angelini, Dana
    Funchain, Pauline
    Sussman, Tamara A.
    Sleiman, Joseph
    Ornstein, Moshe C.
    McCrae, Keith
    Khorana, Alok A.
    TARGETED ONCOLOGY, 2022, 17 (05) : 563 - 569
  • [43] Clinical Outcomes of Cetuximab and Paclitaxel after Progression on Immune Checkpoint Inhibitors in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
    Suzuki, Shinsuke
    Toyoma, Satoshi
    Kawasaki, Yohei
    Koizumi, Koh
    Iikawa, Nobuko
    Shiina, Kazuhiro
    Endo, Tentaro
    Abe, Tomoe
    Kouga, Teppei
    Yamada, Takechiyo
    MEDICINA-LITHUANIA, 2021, 57 (11):
  • [44] Outcomes following long-term response to immune checkpoint inhibitors in patients with advanced melanoma
    Handel, Eleanor
    McKeown, Janet
    Wei, Joe
    Kankaria, Roma
    Burnette, Hannah
    Lawless, Aleigha
    Czapla, Juliane
    Albrecht, Lea Jessica
    Mangana, Joanna
    Kessels, Jolien Isabel
    Allayous, Clara
    Boatwright, Christina Ann
    Ottaviano, Margaret
    Czarnecka, Anna Malgorzata
    Rutkowski, Piotr
    Lo, Serigne N.
    Long, Georgina V.
    Menzies, Alexander M.
    Carlino, Matteo S.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [45] Impact of pre-treatment body mass index on patients with head and neck cancer treated with radiation
    Tsang, Ngan M.
    CANCER RESEARCH, 2012, 72
  • [46] Outcomes of immune checkpoint inhibitors in patients with metastatic uveal melanoma treated with tebentafusp
    Koch, E. C.
    Ceballos, D. P. Arteaga
    Vilbert, M.
    Lajkosz, K.
    Muniz, T. Pimentel
    Hirsch, I.
    Ribeiro, M. F. Silva Almeida
    Mantle, L.
    Anczurowski, M.
    Hogg, D.
    Saibil, S.
    Spreafico, A.
    Krema, H.
    Butler, M. O.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S928 - S928
  • [47] Endocrine Toxicity and Outcomes in Patients With Metastatic Malignancies Treated With Immune Checkpoint Inhibitors
    Al Ashi, Suleiman, I
    Thapa, Bicky
    Flores, Monica
    Ahmed, Ramsha
    Rahim, Shab E. Gul
    Amir, Maryam
    Alomari, Mohammad
    Chadalavada, Pravallika
    Morrison, Shannon L.
    Bena, James F.
    Hercbergs, Aleck
    Lashin, Ossama
    Daw, Hamed
    JOURNAL OF THE ENDOCRINE SOCIETY, 2021, 5 (08)
  • [48] Sarcopenia as predictive factor of response to nivolumab in recurrent-metastatic head and neck (RM-SCCHN) cancer patients
    Schipilliti, F. M.
    Pecchi, A.
    Trudu, L.
    Napolitano, M.
    Spallanzani, A.
    Valoriani, F.
    Reverberi, L.
    Prampolini, F.
    Martelli, F.
    Depenni, R.
    Dominici, M.
    Bertolini, F.
    ANNALS OF ONCOLOGY, 2020, 31 : S676 - S676
  • [49] Association of autoimmunity with survival in patients with recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) treated with immune checkpoint inhibitors (ICIs).
    Economopoulou, Panagiota
    Gavrielatou, Niki
    Papaxoinis, George
    Kotsantis, Ioannis
    Pantazopoulos, Anastasios
    Anastasiou, Maria
    Kavourakis, George
    Gkolfinopoulos, Stavros
    Psyrri, Amanda
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [50] Long-term survivors among patients with metastatic melanoma treated with targeted agents and/or checkpoint inhibitors
    Linardou, H.
    Laskarakis, A.
    Molfeta, A.
    Sakellariou, K.
    Tarampikou, A.
    Soroli, E.
    Gkiati, K.
    Bafaloukos, D.
    ANNALS OF ONCOLOGY, 2018, 29
12345